PHARVARIS N.V. EO -12 (F:9EN) — Market Cap & Net Worth
Market Cap & Net Worth: PHARVARIS N.V. EO -12 (9EN)
PHARVARIS N.V. EO -12 (F:9EN) has a market capitalization of $1.67 Billion (€1.43 Billion) as of August 6, 2026. Listed on the F stock exchange, this Germany-based company holds position #6765 globally and #979 in its home market, demonstrating a -2.85% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PHARVARIS N.V. EO -12's stock price €29.00 by its total outstanding shares 65407822 (65.41 Million). Review PHARVARIS N.V. EO -12 balance sheet liabilities to assess the company's total debt and financial obligations.
PHARVARIS N.V. EO -12 Market Cap History: 2021 to 2026
PHARVARIS N.V. EO -12's market capitalization history from 2021 to 2026. Data shows growth from $1.06 Billion to $2.22 Billion (5.62% CAGR).
PHARVARIS N.V. EO -12 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PHARVARIS N.V. EO -12's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9EN by Market Capitalization
Companies near PHARVARIS N.V. EO -12 in the global market cap rankings as of August 6, 2026.
Key companies related to PHARVARIS N.V. EO -12 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #544 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #569 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $478.71 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $760.66 |
| #544 | Argen-X | BR:ARGX | $49.55 Billion | €728.00 |
| #569 | UCB SA | BR:UCB | $47.34 Billion | €223.30 |
PHARVARIS N.V. EO -12 Historical Marketcap From 2021 to 2026
Between 2021 and today, PHARVARIS N.V. EO -12's market cap moved from $1.06 Billion to $ 2.22 Billion, with a yearly change of 5.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.22 Billion | +34.26% |
| 2025 | €1.65 Billion | +18.68% |
| 2024 | €1.39 Billion | -27.20% |
| 2023 | €1.91 Billion | +142.72% |
| 2022 | €787.63 Million | -25.90% |
| 2021 | €1.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 5th, 2026 the market cap of PHARVARIS N.V. EO -12 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.67 Billion USD |
| MoneyControl | $1.67 Billion USD |
| MarketWatch | $1.67 Billion USD |
| marketcap.company | $1.67 Billion USD |
| Reuters | $1.67 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more